The U.S. Food and Drug Administration has approved the first gene therapy designed to restore hearing in children born with a rare form of genetic deafness, marking a historic breakthrough in the treatment of hearing loss. The decision opens the door for a new class of medicines that target the root cause of deafness rather than relying on devices like cochlear implants. Researchers and families alike are calling the approval a turning point for the field.
The therapy, developed by Regeneron Pharmaceuticals, targets children born with a defective version of the OTOF gene, which prevents the production of a protein called otoferlin. This protein is essential for the inner ear’s hair cells to transmit sound signals to the brain. In the treatment, doctors make a small incision behind the ear and infuse billions of harmless adeno-associated viruses carrying a healthy copy of the OTOF gene. Within weeks, most patients began hearing for the first time. According to Regeneron, 80% of the 20 treated patients achieved significant hearing restoration, and 42% gained normal hearing, including the ability to hear whispers. The benefits have lasted at least two years so far.
“It’s the first time in history there’s a new drug for hearing loss,” said Dr. Zheng-Yi Chen, an associate scientist at Mass Eye and Ear who was not involved in the therapy. “I think it’s a historical event, a landmark, a great development for the whole field.” The approval is especially meaningful for families like that of Sierra Smith, whose son Travis was born profoundly deaf. After treatment at Columbia University, Travis startled at his mother’s laugh for the first time. “That was like the most surreal moment a mother can feel when your son first hears your voice,” Smith said.
The therapy is currently approved only for the roughly 50 children born each year in the U.S. with OTOF-related deafness. Regeneron plans to offer the treatment free of charge in the United States, and it should be available within weeks. While this specific therapy addresses a rare condition, researchers are already exploring similar gene therapies for other forms of genetic deafness. Some experts hope the approach could one day be adapted for more common types of hearing loss, such as those caused by aging or loud noise.
For now, the approval represents a new era for families who previously had no medical option. “After a family found out their child had been born with hearing loss, no one was ever able to say: ‘We have a treatment so that they can hear,’” said Dr. Jonathon Whitton of Regeneron. “Now for the first time we are talking about medicines that actually enable the ear to hear. It’s the beginning of a new era, honestly.” As research continues, the hope is that more children like Travis will gain access to treatments that restore not just hearing, but the simple joy of hearing a parent’s voice.